<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F31D4947-708C-4E72-8A87-651B54C39C8B"><gtr:id>F31D4947-708C-4E72-8A87-651B54C39C8B</gtr:id><gtr:firstName>Majlinda</gtr:firstName><gtr:surname>Lako</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E041E319-E561-4A17-916C-DCF2EC196DD9"><gtr:id>E041E319-E561-4A17-916C-DCF2EC196DD9</gtr:id><gtr:firstName>Lyle</gtr:firstName><gtr:surname>Armstrong</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B6EFF9E5-B4EE-43F8-A49B-E2ED55DE93B2"><gtr:id>B6EFF9E5-B4EE-43F8-A49B-E2ED55DE93B2</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:surname>Chinnery</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FI020209%2F1"><gtr:id>F42FD8F2-B879-4683-84EF-036D15F1EB5F</gtr:id><gtr:title>Mitochondrial function and transition from glycolysis to oxidative phosphorylation in differentiating induced pluripotent stem cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/I020209/1</gtr:grantReference><gtr:abstractText>Induced pluripotent stem cells (iPSC) can be derived from human tissues such as the skin and have two characteristic properties. Firstly, we can grow them indefinitely in the laboratory in either small or large scale and secondy, by use of appropriate methods, they seem to be able to differentiate into almost all of the cell types found in the adult body. At a first glance this makes them similar to human embryonic stem cells which have been hailed as an attractive resource for regenerative procedures that involve transplantation of specific differentiated cells into human patients. Embryonic stem cells are derived from individual Human embryos so any cells we produce form these cell lines are likely to be rejected by the body's immune system. iPSC should not suffer from this problem if the cells we make from them are transplanted back into the same individual from which they were made but there is a potentially greater advantage of iPSC namely the creation of 'disease in a dish' models. This relies upon making an iPSC line from a patient suffering from a genetic disease then differentiating that iPSC line to the type of cells affected by the disease so we can see what problems arise and how we might be able to fix them. All of this relies upon the hiPSC line being able to differentiate into cells that are functionally identical to those found in the body. Available evidence and our pilot data suggest that although they may produce cells that look similar to adult cells (such as those of the bone marrow or the nervous system), these may not work as effectively as the genuine article therefore in order to realize the promise of iPSC technology, we have to find out why they are defective and develop ways to fix these problems. Our pilot data suggest that problems with mitochondria, the energy suppliers of the cell, may be a significant reason why iPSC and their differentiated problem could be dysfunctional. Mitochondria exist as distinct structures within the cell and while some of their components are produced from their own indepdent genes, the majority of their structure and function is controlled by genes residing in the cells nucleus. The ways in which mitochondria function are quite different in various cell types; for example hESC don't use them to generate energy very much but differentiated cells derived from hESC do. The human cells (somatic cells) we reprogram to make hiPSC fall into the latter category but it seems that the reprogramming is incomplete and hiPSC may still try to control their mitochondria in similar ways to the original somatic cells. This is potentially bad for the survival of the hiPSC but even worse, they may not be able to regulate mitochondria properly on differentiation. In view of this our objectives are to compare the mitochondria of hiPSC and hESC and then differentiate them to three cell types with differing energy requirements (and therefore different mitochondrial regulation). We will compare the expression of genes involved in mitochondrial function, analyse their control mechanisms and attempt to explain why this might not work optimally. Once this understanding is gained, we will be able to develop means to solve these problems and produce hiPSC with fullly functional mitochondria although this in turn may allow us to improve other aspects of iPSC function that rely upon completion of reprogramming. The successful execution of this project will be enormously beneficial not only to ours and other groups investigating iPSC biology but it will also promote development of disease treatments using these cells which will provide significant social and economic impact.</gtr:abstractText><gtr:technicalSummary>Our pilot data suggest that the mitochondria of induced pluripotent stem cells (iPSC), may not function in an analogous manner to those of human embryonic stem cells (hESC). There are similarities in terms of mitochondrial genome copy number and mitochondrial mass in both hiPSC and hESC but mitochondrial membrane potential and production of superoxide are significantly lower in iPSC. In addition, several nuclear encoded genes central to mitochondrial function, are mis-expressed compared to hESC both in the pluripotent cells and their differentiated progeny. Crucially, the extent to which mis-expression occurs varies between isogneic iPSC lines suggesting that the causes of these differences may be epigenetic and implies that the epigenetic reprogramming originally required to generate the iPSC from dermal fibroblasts may have been incomplete. If this is a general phenomenon with iPSC, they could be a poor source of cells for regenerative medicine or disease modelling so we plan to analyse mitochondrial parameters such as morphology, membrane potential and expression levels of genes associated with mitochondrial function across a range of hiPSC and hESC lines and somatic cell types we can produce from them. This point is important since hiPSC and hESC do not use the oxidative phosphorylation ATP generation system intrinsic to the mitochondria to the same extent as many somatic cells. It is therefore important to determine that hiPSC are capable of generating the numbers of mitochondria required by the somatic cell types they differentiate into and that these mitochondria function in the same way as we would expect of the progeny of hESC. We will analyse mitochondrial numbers and morpholgy using established histochemical staining protocols but the key steps of this proposal will be analyses of gene expression using microarrays and epigenetic architecture of nuclear encoded mitchondrial associated genes using chromatin immunoprecipitation.</gtr:technicalSummary><gtr:potentialImpactText>Since the first publication detailing the derivation of Human iPSC in 2007, nearly two thousand articles have appeared in the scientific literature describing new methods to generate these cells and the attempts to develop protocols for their differentiation into somatic cells with potential clinical uses. Many studies of this type were already in progress using embryonic stem cells but the enormous advantage of iPSC is that they are isogenic with the individual from whom they are derived. If however they do not behave in the same predictable manner as ESC, they may not be so useful either as a source of cells in regenerative medicine or as in vitro models of human diseases. This proposal aims to determine if mitochondria in iPSC behave in a similar fashion to those of ESC and to explain any differences in terms of incomplete epigenetic reprogramming or other factors that contribute to mitochondrial function. Moreover, if the dysfunction results from problems with epigenetic regulation of nuclear encoded genes associated with mitochondrial activity, we hope to be able to 'repair' this so the mitochondria behave in a more normal fashion. In view of this, the most immediate group to benefit from our research will be the large number of academic groups who are working with iPSC as we have described in the academic beneficiaries section however the potential benefits of this work extend beyond the boundaries of purely academic research. Clinical trials are beginning with embryonic stem cell derived somatic cells so it is highly probable that iPSC represent the next logical step in development of stem cell based therapies if current problems with their growth and differentiation parameters can be overcome. A recent article in Nature Biotechnology (Nat Biotech 2010, 28(6):535-536) further underlines considerable industrial interest in pluripotent stem cells as sources of clinically useful tissue thus the results of this project are highly likely to be beneficial to the future utility of iPSC in commercial regenerative medicine. Regenerative medicine is likely to have a highly significant economic impact upon nations with the scientific and financial capabilities needed to implement its development. To set this statement in context, the USA currently spends $175.8 billion annually for the treatment of diabetes and myocardial infarction, two conditions which are primary targets for stem cell based regenerative therapies. The United Kingdom is a leading contributor to Stem Cell related research and if the results of this project allow the development of clinically useful iPSC, and these can undergo successful translation into commercial cell therapy products, the economic benefits to the UK will be considerable. The social impact of such developments cannot be understated. If effective treatments for the two conditions mentioned above and others arise, even indirectly from the results of this project we will have contributed in an effective way to improving the health and quality of life of significant numbers of individuals both in the UK and in other countries.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-02-23</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-02-24</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>325885</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>nternational Society for Stem Cell Research (ISSCR), Boston MA, USA.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9724B468-3EED-4559-B004-FE62CA75713E</gtr:id><gtr:impact>invited presentation on induced pluripotent stem cell banking to ISSCR</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISSCR poster &quot;Improving our understanding of autosomal dominant retinitis pigmentosa using PRPF31 patient specific induced pluripotent stem cells&quot; 24th June 2016, San Francisco, USA,</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E77A0BCF-12B6-46DD-84A7-374EE97256D2</gtr:id><gtr:impact>presentation of data to ISSCR</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISSCR poster &quot;A novel role for MiR1305 in regulation of pluripotent-differentiation balance, cell cycle and apoptosis in human pluripotent stem cells, 24th June 2016, San Francisco, USA</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>078B57BA-0451-4FD1-A702-DF58B3C4223E</gtr:id><gtr:impact>presentation of data to ISSCR</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Society for Stem Cell Research (ISSCR), Boston MA, USA.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B605F7F2-FD6A-4525-97F3-36212B23BE57</gtr:id><gtr:impact>Invited speaker in session &amp;quot;generating collections of human iPSC and ES lines&amp;quot;. Possible collaborations explored


none yet</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>StemBANCC consortium meeting, Boehringer Ingelheim, Biberach, Germany</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CB1CB6F6-8F41-4CB1-BFA2-1534C67E3FE5</gtr:id><gtr:impact>decisions reached regarding application of induced pluripotent stem cells in the European pharmaceutical industry

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Covance Ltd, 24th February 2016, &quot;development of iPSC based models of human skin&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0F418C48-C955-4317-9C58-9F36BBFDBFB2</gtr:id><gtr:impact>discussion about how we can use iPSC to build full thickness models of human skin</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Takeda Science Foundation Symposium on Pharmaceutical Sciences</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>83D59472-F711-491C-8D8B-B67679A25F85</gtr:id><gtr:impact>the outcome of this talk was increasing the integration of my research group into the international stem cell community with some possible leads to future international collaborations

no impacts yet</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Tissue Regeneration &amp; Stem Cell Network seminar series, Manchester University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C3F7C745-4152-4C59-AAED-D3E73BEF205B</gtr:id><gtr:impact>described my groups work on induced pluripotent stem cells to academics in Manchester University. Generated useful and stimulating discussions

none yet</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to StemBANCC general assembly, Chilly-Mazarin, Paris, France, &quot;Pluripotent stem cell based models&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>90B0E2A8-66D2-47A6-BD2D-E84FA87754D3</gtr:id><gtr:impact>discussion / update of investigations into the utility of pluripotent stem cells as tools to model human disease</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Imanova, Ltd, 18th February 2016, iPSC for disease modelling&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FEF12E56-25E0-498E-BD10-F80EC0B15141</gtr:id><gtr:impact>demonstrating the use of stem cells in drug discovery</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Cardiff University, 8th July 2016, Induced Pluripotent Stem Cell modelling of cardiac disease&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A9B02634-A258-49BB-9F88-5B05DF8349A7</gtr:id><gtr:impact>presentation and discussion of the application of pluripotent stem cells to modelling congenital heart abnormailities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>StemBANCC consortium meeting, Janssen Pharmaceuticals, Beerse, Belgium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D8BBDBF-8D8F-45DB-B70E-FC6EE3304D31</gtr:id><gtr:impact>presented data obtained during stembannc project but this led to important discussions about the requirements of the European Pharmaceutical industry for cells to be used in drug screening

none yet</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle University Molecular Biosciences Research day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7ECE503A-BCF7-4DC1-9BC9-F7E7CE2BCB43</gtr:id><gtr:impact>Discussions resulted in more possible collaborations

No notable impacts so far</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Eurodiagnostica, Malmo, Sweden, 14th December 2016, Reprogramming drug discovery and development</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1D48FEF8-1EDB-4F7F-806D-915D1F0FB243</gtr:id><gtr:impact>investigating the utility of pluripotent stem cells as diagnostic tools in medicine</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NESCI Research Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF8523FA-3DE4-4A9C-8876-76B0E6B9D6AE</gtr:id><gtr:impact>keynote lecture entitled &amp;quot;disease modelling with iPSC&amp;quot;

no notable impacts</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Aptus Clinical,Manchester, 9th February 2017&quot; Reprogramming drug discovery and development - the science of induced pluripotent stem cells&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1F54DB33-40C5-4ECF-AF13-9011BD1F1A66</gtr:id><gtr:impact>increasing industrial interest in use of stem cells for drug discovery</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Charles River, Edinburgh, 7th February 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF82A555-F03E-475B-B567-C6597DBA6989</gtr:id><gtr:impact>discussion about using pluripotent stem cells to replace animal models of drug toxicity</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Domainex, Ltd, 2nd March 2016, &quot;iPSC for disease modelling&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EBD0F60B-2291-425A-84D9-6403DAB16D32</gtr:id><gtr:impact>promoting iPSC for disease modelling</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISSCR poster W2084, June 22nd 2016, San Francisco, USA, &quot;CHCHD2 primes the differentiation potential of human induced  pluripotent stem cells to neuroectodermal lineages&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>82104FCD-76F1-4077-86A9-74B9A3FD4E25</gtr:id><gtr:impact>presentation of data to the International Society for Stem Cell Research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to UK Biobank, Stockport, UK, 26th February &quot;Generation and characterisation of iPSC from small volumes of cryopreserved peripheral blood&quot;</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EDB34310-34DE-4B92-82F5-DEC24754A87F</gtr:id><gtr:impact>discussed how we might be able to expand the impact of the resources held in the UK biobank by deriving pluripotent stem cells</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Using human pluripotent stem cells to understand and treat inherited diseases</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AF018C29-CBC3-4047-8FEB-B686E34373AE</gtr:id><gtr:impact>Invited Lecture at the Annual meeting of the British Society of Human Genetics Conferences

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovative Medicines Initiative - EBiSC</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>IMI grant agreement No 115582</gtr:fundingRef><gtr:id>5B18D5AF-3623-4633-AE88-FAF3F0151A63</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>61997</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC confidence in concept:</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>C9F18935-1D8D-47D7-B6EB-0F79EF842E1E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99981</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NCR3R CrackiT: 3D hiPSC derived laminated retina model: &amp;pound; 99,981.87, Coinvestigator</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>F108280F-0612-4A02-A654-41A41C3A6DC5</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie-Curie training fellowship</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Marie Curie Actions</gtr:fundingOrg><gtr:id>0F1E5291-4F63-4D16-B83D-090676A66A01</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovative Medicines Initiative - StemBANNC</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>IMI grant agreement No 115439</gtr:fundingRef><gtr:id>002A968A-04FB-4BA8-AFCC-0A9E7F85CE43</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Health and Medical Research Council (Australia)</gtr:department><gtr:description>Integrated MRes/PhD studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Australian Government</gtr:fundingOrg><gtr:id>2641826D-5342-4568-B7BB-8C22EC74D832</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3R: CRACK-IT challenge 20: METABODERM;</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>557E49F5-AC00-43FD-BCBC-1914B4FCDDAC</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>responsive mode</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Macular Society</gtr:fundingOrg><gtr:id>E2CD3BAC-99E2-4495-A22F-5F7B1717E0ED</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>responsive mode</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Charity</gtr:fundingOrg><gtr:id>3265FD74-3B20-44A2-8539-BF6D8EE8BF83</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49990</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>responsive mode</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Charity</gtr:fundingOrg><gtr:id>D2810D69-470E-4608-8E9A-FBE237E53399</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The knowledge gained from this investigation has contributed in part to our ability to use induced pluripotent stem cells to model a range of diseases in vitro. In turn, this has contributed to the foundation of s spin out company (Newcells Biotech Ltd) in which the grant holder (Prof L Armstrong) and Newcastle University hold equity</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>56948887-8126-4E39-BDA0-7B4594A5D64D</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Human induced pluripotent stem cells (hiPSC) utility is limited by variations in their ability to undergo lineage specific differentiation. We have undertaken a transcriptional comparison of human embryonic stem cell lines (hESC) and hiPSC lines and have shown that hiPSC are inferior in their ability to undergo neuroectodermal differentiation. We have identified CHCHD2, whose expression is much lower in hiPSC when compared to hESC and can be used as a marker to predict the neuroectodermal differentiation potential of hiPSC. We provide evidence that the hiPSC variability with respect to CHCHD2 expression and differentiation potential is caused by clonal variation during the reprogramming process and that CHCHD2 primes neuroectodermal differentiation of hESC and hiPSC through regulating the activity of the TGF? signalling pathway. The potential utility of using CHCHD2 as a marker for assessing and comparing the hiPSC clonal and/or line differentiation potential provides a tool for large scale differentiation and hiPSC banking studies.</gtr:description><gtr:exploitationPathways>The preliminary investigations that led to this project suggested possible problems with regulation of mitochondrial oxidative phosphorylation in induced pluripotent stem cells. The data we obtained from this investigation indicate that a specific gene, CHCHD2, seems to be involved in controlling differentiation of pluripotent stem cells and may also have functions in the mitochondria but most importantly, these findings enhance our knowledge of the mechanisms that maintain pluripotency. This contributes to the development of more effective ways to use pluripotent stem cells for investigations in developmental biology, drug discovery and potentially as cell sources for regenerative medicine</gtr:exploitationPathways><gtr:id>986D87C8-577F-4FF6-803B-3523F54DD134</gtr:id><gtr:sectors><gtr:sector>Education,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Newcells Biotech Ltd</gtr:companyName><gtr:description>Newcells Biotech Ltd is a spin-out company from the Armstrong /Lako pluripotent stem cell research laboratories situated in the Institute of Genomic medicine, Newcastle University, Newcastle upon Tyne, UK. Its concept is to establish and commercialise model systems for efficacy and toxicity testing in drug discovery programmes within the pharmaceutical industry. Newcells Biotech offers a bespoke service for the generation of somatic cells derived from Induced Pluripotent Stem Cells created from tissue samples collected under informed consent from patients with a range of monogenetic and complex diseases. Prof. Lyle Armstrong, CSO has extensive experience in the generation, culture and differentiation of pluripotent stem cells. He is a founding member of Newcells Biotech Ltd where he is responsible for scientific oversight of research and development operations and strategic direction of the company.</gtr:description><gtr:id>6D1343F7-EF6F-47F7-B818-BD2C6A778089</gtr:id><gtr:impact>the company is in the process of establishing business with several major pharmaceutical companies</gtr:impact><gtr:url>http://www.newcellsbiotech.co.uk/</gtr:url><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99653253-9287-4BD9-AB4F-FC7D23DD10E3"><gtr:id>99653253-9287-4BD9-AB4F-FC7D23DD10E3</gtr:id><gtr:title>A Novel Role for miR-1305 in Regulation of Pluripotency-Differentiation Balance, Cell Cycle, and Apoptosis in Human Pluripotent Stem Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d349f0ce1af7c8c10ad44a2b44fed65d"><gtr:id>d349f0ce1af7c8c10ad44a2b44fed65d</gtr:id><gtr:otherNames>Jin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D60B6B3A-6777-45F2-B44D-14545F60760B"><gtr:id>D60B6B3A-6777-45F2-B44D-14545F60760B</gtr:id><gtr:title>Editorial: Our top 10 developments in stem cell biology over the last 30 years.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35327529ca4f1df9cff05f5b7d814159"><gtr:id>35327529ca4f1df9cff05f5b7d814159</gtr:id><gtr:otherNames>Armstrong L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5FB8AA7C-008C-48E9-B5F5-6856F404DC17"><gtr:id>5FB8AA7C-008C-48E9-B5F5-6856F404DC17</gtr:id><gtr:title>JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4725828763ea18f9bb08c64817c6472f"><gtr:id>4725828763ea18f9bb08c64817c6472f</gtr:id><gtr:otherNames>Neganova I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/430C4638-64F5-4104-8865-45F06A25B252"><gtr:id>430C4638-64F5-4104-8865-45F06A25B252</gtr:id><gtr:title>Brief Report: Inhibition of miR-145 Enhances Reprogramming of Human Dermal Fibroblasts to Induced Pluripotent Stem Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6a7d043f9ead19fb2476e7ac52aeab9e"><gtr:id>6a7d043f9ead19fb2476e7ac52aeab9e</gtr:id><gtr:otherNames>Barta T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5615E555-0776-43F0-B040-9DEB20E93BE1"><gtr:id>5615E555-0776-43F0-B040-9DEB20E93BE1</gtr:id><gtr:title>A critical role for p38MAPK signalling pathway during reprogramming of human fibroblasts to iPSCs.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4725828763ea18f9bb08c64817c6472f"><gtr:id>4725828763ea18f9bb08c64817c6472f</gtr:id><gtr:otherNames>Neganova I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/246B97FE-A859-4059-AAA8-36A8A7F1C725"><gtr:id>246B97FE-A859-4059-AAA8-36A8A7F1C725</gtr:id><gtr:title>The mitochondrial protein CHCHD2 primes the differentiation potential of human induced pluripotent stem cells to neuroectodermal lineages.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc457f2ca8a244fd9a11f99914aec1bb"><gtr:id>cc457f2ca8a244fd9a11f99914aec1bb</gtr:id><gtr:otherNames>Zhu L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/935E2768-BCE3-4C2F-AD32-4CDED186A43D"><gtr:id>935E2768-BCE3-4C2F-AD32-4CDED186A43D</gtr:id><gtr:title>Concise Review: Getting to the Core of Inherited Bone Marrow Failures.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1ec93291033fb46554d744cbc2525eed"><gtr:id>1ec93291033fb46554d744cbc2525eed</gtr:id><gtr:otherNames>Adam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6ACB6BD6-3FC7-4A01-8995-B1641C30B3D3"><gtr:id>6ACB6BD6-3FC7-4A01-8995-B1641C30B3D3</gtr:id><gtr:title>Concise review: the epigenetic contribution to stem cell ageing: can we rejuvenate our older cells?</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35327529ca4f1df9cff05f5b7d814159"><gtr:id>35327529ca4f1df9cff05f5b7d814159</gtr:id><gtr:otherNames>Armstrong L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B968F0DA-9BC9-4E59-A30B-11860C7ABD8D"><gtr:id>B968F0DA-9BC9-4E59-A30B-11860C7ABD8D</gtr:id><gtr:title>Induced pluripotent stem cells : it looks simple but can looks deceive?</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb15855be4efb413999bcd624a98656e"><gtr:id>cb15855be4efb413999bcd624a98656e</gtr:id><gtr:otherNames>Lako M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA50B734-2945-4F9D-9B86-493D7DCDED49"><gtr:id>FA50B734-2945-4F9D-9B86-493D7DCDED49</gtr:id><gtr:title>Potential for pharmacological manipulation of human embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ff0b01918e51ffde4611885b3795d05"><gtr:id>8ff0b01918e51ffde4611885b3795d05</gtr:id><gtr:otherNames>Atkinson SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/698030BA-D92D-429B-96E2-FD4B56A5119C"><gtr:id>698030BA-D92D-429B-96E2-FD4B56A5119C</gtr:id><gtr:title>Brief report: human pluripotent stem cell models of fanconi anemia deficiency reveal an important role for fanconi anemia proteins in cellular reprogramming and survival of hematopoietic progenitors.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90beae265cc66a609b94676c64beab85"><gtr:id>90beae265cc66a609b94676c64beab85</gtr:id><gtr:otherNames>Yung SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4DAF6391-E13B-43A7-AF75-F3A8A4B5F610"><gtr:id>4DAF6391-E13B-43A7-AF75-F3A8A4B5F610</gtr:id><gtr:title>An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiac myocytes.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f7d6414b5561959e026a21adb7b56753"><gtr:id>f7d6414b5561959e026a21adb7b56753</gtr:id><gtr:otherNames>Jiang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74341612-1EE3-4E2F-A2D5-2B463BFCF265"><gtr:id>74341612-1EE3-4E2F-A2D5-2B463BFCF265</gtr:id><gtr:title>Epigenetics</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5442854637d98ee13f33248d9e31ff68"><gtr:id>5442854637d98ee13f33248d9e31ff68</gtr:id><gtr:otherNames>Armstrong Lyle</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9780815365112</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C368D598-5587-44ED-B53D-E902BB94B26C"><gtr:id>C368D598-5587-44ED-B53D-E902BB94B26C</gtr:id><gtr:title>Neural stem cells, a step closer to clinic?</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d61a61b7d2ee0407b73f296130f13efa"><gtr:id>d61a61b7d2ee0407b73f296130f13efa</gtr:id><gtr:otherNames>Stojkovic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3CCCB18D-F3CF-4CBB-81EA-09C49D3305A1"><gtr:id>3CCCB18D-F3CF-4CBB-81EA-09C49D3305A1</gtr:id><gtr:title>Multiplex High-Throughput Targeted Proteomic Assay To Identify Induced Pluripotent Stem Cells.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b8624cba5397e3f926bb9992f0b0cc59"><gtr:id>b8624cba5397e3f926bb9992f0b0cc59</gtr:id><gtr:otherNames>Baud A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3977FE09-41EB-41C4-A070-B5A402B289D8"><gtr:id>3977FE09-41EB-41C4-A070-B5A402B289D8</gtr:id><gtr:title>Concise Review: Cardiac Disease Modeling Using Induced Pluripotent Stem Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/851a472230d2cd69a9cab22daa89e275"><gtr:id>851a472230d2cd69a9cab22daa89e275</gtr:id><gtr:otherNames>Yang C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44EF5B75-8AB6-4525-BE4B-773EE478BD42"><gtr:id>44EF5B75-8AB6-4525-BE4B-773EE478BD42</gtr:id><gtr:title>Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ac8dda101d738f96423f3e6d8bd9cce1"><gtr:id>ac8dda101d738f96423f3e6d8bd9cce1</gtr:id><gtr:otherNames>International Stem Cell Initiative</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/I020209/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>